After losing race for first to market in lupus nephritis, Aurinia taps Otsuka for voclosporin licensing pact abroad

After losing race for first to market in lupus nephritis, Aurinia taps Otsuka for voclosporin licensing pact abroad

Source: 
Endpoints
snippet: 

Tiny biotech Aurinia Pharmaceuticals is looking to slay a giant in GlaxoSmithKline’s Benlysta — which just scored a big approval in lupus nephritis — with its late-stage voclosporin on the cusp of an FDA approval. Looking to take its commercial plans global, Aurinia has tapped a Japanese pharma to accelerate its potential voclosporin launch.